ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The San Diego–based biotech firm Plexium has raised $102 million in funding to further develop its targeted protein degradation technology. Plexium’s DNA-encoded-library-based screening platform is designed to find small molecules that bind to E3 ligases, which modulate protein destruction. The company says it has raised almost $200 million since its 2019 launch. It formed an oncology drug discovery partnership with Amgen earlier this month.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X